Table 2. Patients and specimens in the study.

Case No.	Sample type	Country	Year	Clinical group	Days after onset	Genotype
1	OF	UK	2003	P	9	H
2	OF	UK	2003	P	10	H
3	OF	UK	2004	P	6	G
4	OF	UK	2004	P	6	G
5	OF	UK	2004	P	7	G
6	OF	UK	2004	P	6	G
7	OF	UK	2004	P	8	H
8	OF	UK	2004	P	7	J
9	OF	UK	2005	P	6	G
10	OF	UK	2005	P	6	J
11	OF	UK	2005	P	6	G
12	OF	UK	2005	P	7	G
13	OF	DOM	2005	P	NK	H*
14	OF	UK	2005	P	7	J
15	OF	UK	2005	P	5	G
16	OF	UK	2005	P	5	J
17	TS	UK	2004	P	NK	C
18	TCF-TS	UK	1998	P	NK	C
19	TCF-TS	UK	2000	P	NK	C
20	TCF-NK	UK	2004	P	NK	D
21	TCF-TS	China	2005	P	NK	F
22	TCF-TS	China	2005	P	NK	F
23	CSF	UK	2004	N	8	D
24	CSF	UK	2004	N	NK	G
25	CSF	UK	2004	N	1	G
26	CSF	UK	2004	N	NK	G
27	CSF	UK	2005	N	NK	G
28	CSF	UK	2005	N	NK	G
29	CSF	UK	2005	N	6	G
30	CSF	UK	2005	N	NK	G
31	CSF	UK	2005	N	NK	G
32	CSF	UK	2005	N	NK	G
33	CSF	UK	2005	N	NK	G
34	CSF	UK	2005	N	NK	G
35	CSF	China	2004	N	NK	F
36	CSF	China	2004	N	NK	F
37	TCF-TS	China	2008	N	NK	F
38	TCF-TS	China	2008	N	NK	F
39	TCF	China	2002	N	NK	F

Note: OF, Oral fluid; CSF, cerebrospinal fluid; TS, throat swab; TCF, tissue culture fluid; P, parotitis; N, neurological complications; NK: not known; MMR, measles-mumps-rubella vaccine; UK, United Kingdom.

^*Dominican Republic linked re-infection case in Sweden, childhood infected (Dr. Kari Johansen, Swedish Institute for Infectious Disease Control).